Newsroom | 33162 results
Sorted by: Latest
-
Mirion Medical to Debut New Solutions, Highlight Broad Radiopharma-Focused Portfolio at SNMMI Annual Meeting
ATLANTA--(BUSINESS WIRE)--Mirion, a global leader in radiation safety, science, and medicine, announced today that its Mirion Medical group will showcase its portfolio of solutions designed to enable the radiopharma and theranostic fields at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 21-24, in New Orleans, Louisiana. New products from Capintec and Dosimetry Services will be introduced alongside innovations from the broader Mirion portfolio, including...
-
The Sun’s Out. So Is the Secret to UV and Sun Support from Within.
KAILUA-KONA, Hawaii--(BUSINESS WIRE)--Science has evolved for smarter sun care. BioAstin® Hawaiian Astaxanthin® delivers clinically backed sun support from within with powerful microalgae....
-
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025
LYON, France--(BUSINESS WIRE)--MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025...
-
PharmaJet® and Immuno Cure Sign Agreement for Clinical Development of a Needle-free HIV Therapeutic DNA Vaccine
GOLDEN, Colo.--(BUSINESS WIRE)--Agreement with Immuno Cure adds to PharmaJet's portfolio of global development partnerships with innovative oncology & infectious disease developers....
-
Quantum-Si to Join Leading Experts from DNAnexus, Olink, and Northwestern in Upcoming GenomeWeb Webinar on Proteomics Data Integration and Standardization
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Join Leading Experts from DNAnexus, Olink, & Northwestern in Upcoming GenomeWeb Webinar on Proteomics Data Integration & Standardization...
-
Resumen: Brenus Pharma e InSphero han desarrollado esferoides tumorales en 3D que imitan las condiciones in vivo del cáncer colorrectal humano y confirman la eficacia de STC-1010
LISBOA, Portugal--(BUSINESS WIRE)--Brenus Pharma, empresa biotecnológica francesa dedicada al desarrollo de inmunoterapias innovadores de nueva generación, e InSphero, líder suizo en tecnologías de ensayos basadas en células 3D, presentaron datos prometedores en el congreso anual de la Asociación Europea para la Investigación del Cáncer 2025. Estos datos corroboran el uso de esferoides tumorales 3D para evaluar la eficacia de STC-1010, el principal candidato de Brenus contra el cáncer colorrect...
-
Brenus Pharma et InSphero ont mis au point des sphéroïdes tumorales 3D imitant les conditions in vivo de cancer colorectal humain et confirmant l'efficacité du STC-1010
LISBONNE, Portugal--(BUSINESS WIRE)--Brenus Pharma, la biotech française développant des immunothérapies de nouvelle génération, et InSphero, le chef de file suisse des technologies d'analyse 3D à base de cellules, ont présenté des données prometteuses lors du congrès annuel 2025 de l'Association européenne pour la recherche sur le cancer. Ces données confirment l’utilisation de sphéroïdes tumoraux 3D pour le test de puissance du STC-1010, candidat principal de Brenus dans le traitement du canc...
-
Brenus Pharma und InSphero haben 3D-Tumorsphäroide entwickelt, die in vivo menschliche Darmkrebserkrankungen nachahmen und die Wirksamkeit von STC-1010 bestätigen
LISSABON, Portugal--(BUSINESS WIRE)--Brenus Pharma, ein französisches Biotechunternehmen, das First-in-Class-Immuntherapien der nächsten Generation entwickelt, und InSphero, ein Schweizer Marktführer bei 3D-Zell-Assay-Technologien, haben auf dem Jahreskongress 2025 der European Association for Cancer Research vielversprechende Daten präsentiert. Diese Daten bestätigen den Nutzen von 3D-Tumorsphäroiden bei der Wirksamkeitsprüfung von STC-1010, dem führenden Wirkstoffkandidaten von Brenus für Dar...
-
Riassunto: Brenus Pharma e InSphero hanno sviluppato sferoidi tumorali tridimensionali che imitano in vivo le condizioni del tumore del colon-retto nell'uomo e confermano l'efficacia di STC-1010
LISBONA, Portogallo--(BUSINESS WIRE)--Brenus Pharma, azienda biotecnologica francese che sviluppa immunoterapie di nuova generazione prime nel settore, e InSphero, un leader svizzero nelle tecnologie di saggi a base cellulare tridimensionali, ha presentato dati promettenti al congresso annuale 2025 della European Association for Cancer Research. Questi dati confermano l'uso di sferoidi tumorali tridimensionali per testare l'efficacia di STC-1010, il principale candidato farmaco per il tumore de...
-
ZAP Surgical anuncia los primeros tratamientos con la plataforma ZAP-X Gyroscopic Radiosurgery en Latinoamérica
SAN CARLOS, California--(BUSINESS WIRE)--ZAP Surgical Systems, Inc. líder mundial en cirugía cerebral robótica no invasiva, anunció hoy los primeros tratamientos de pacientes utilizando su plataforma ZAP-X® Gyroscopic Radiosurgery® en Latinoamérica. Ubicada en Neuland, Boquerón, Paraguay, Radioterapia Concordia (www.saludconcordia.com) ha comenzado oficialmente su uso clínico, marcando un hito importante en la descentralización de la atención vanguardista para tumores cerebrales en toda la regi...
